Details of the Drug

General Information of Drug (ID: DMC1SRK)

Drug Name
ENV-105
Synonyms Carotuximab
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25 Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DQ8K3R

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Endoglin CD105 (ENG) TTB30LE EGLN_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Non-small-cell lung cancer
ICD Disease Classification 2C25
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Endoglin CD105 (ENG) DTT ENG 5.97E-02 -0.74 -0.86
Endoglin CD105 (ENG) DTT ENG 5.97E-02 -0.74 -0.86
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05401110) IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer. U.S.National Institutes of Health.
2 Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells. Front Med (Lausanne). 2022 Sep 7;9:845918.